Product Description
Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Arotinolol)
Mechanisms of Action: ADRB Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Warner Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypertension|Kidney Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PRECISE | N/A |
Not yet recruiting |
Hypertension, Renal|Kidney Failure, Chronic |
2028-12-31 |
|
| CTR20231657 | N/A |
Completed |
Angina Pectoris|Hypertension|Tachycardia|Essential Tremor |
2023-07-16 |
|
| ChiCTR2100049628 | N/A |
Not yet recruiting |
Hypertension |
2022-12-31 |
|
| CTR20211285 | N/A |
Completed |
Angina Pectoris|Tachycardia|Hypertension|Essential Tremor |
2021-08-18 |